Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 51, Issue 2, Pages 183-186Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm701359z
Keywords
-
Categories
Ask authors/readers for more resources
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available